Hycamtin Capsules
Generic name: topotecan hydrochloride
Dosage form: capsule
Drug class:Miscellaneous antineoplastics
Medically reviewed by Drugs.com. Last updated on Sep 1, 2021.
On This Page
- Boxed Warning
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- References
- How Supplied/Storage and Handling
- Patient Counseling Information
HYCAMTIN can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts of greater than or equal to 1,500/mm3 and platelet counts greater than or equal to 100,000/mm3. Monitor blood cell counts [see Warnings and Precautions (5.1)].
Indications and Usage for Hycamtin Capsules
HYCAMTIN® capsules are indicated for the treatment of relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy.
Hycamtin Capsules Dosage and Administration
Recommended Dosage
The recommended dosage of Hycamtin Capsules is 2.3 mg/m2/day orally once daily, with or without food, for 5 consecutive days, starting on Day 1 of a 21-day cycle. Round the dose to the nearest 0.25 mg and prescribe the minimum number of 1 mg and 0.25 mg capsules. Prescribe the same number of capsules for each of the 5 dosing days.
Swallow capsules whole. Do not chew, crush, or divide the capsules.
If a dose of Hycamtin Capsules is missed or vomiting occurs after taking a dose, do not administer an additional dose and take the next dose at the scheduled time.
Dosage Modifications for Adverse Reactions
Diarrhea
Do not administer Hycamtin Capsules to patients with Gr...
